BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10588850
• 负责人: Victoria B Risbrough
• 金额: --
• 依托单位: VA SAN DIEGO HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-10-01 至 2027-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10588850
• 关键词: Acute; Adult; Alcohol consumption; Animal Model; Astrocytes; Award; Behavior; Behavioral; Biological Markers; Biological Psychiatry; CRF receptor type 1; CRF receptor type 2; California; Chronic; Clinical; Clinical Research; Clinical Trials; Cognitive; Collection; Communication; Corticotropin-Releasing Hormone; Country; Department of Defense; Development; Diagnosis; Diagnostic; Disease; Extinction; Fright; Functional disorder; Funding; Future; Genetic; Genetic Polymorphism; Genetic Risk; Health; Healthcare Systems; Hormones; Human; Immune system; Intervention; Journals; K-Series Research Career Programs; Laboratories; Laboratory Research; Learning; Liquid substance; Longevity; Maintenance; Manuscripts; Marines; Mental Health; Mentors; Mentorship; Molecular; Mus; National Institute of Mental Health; National Institute on Alcohol Abuse and Alcoholism; Nature; Nerve Degeneration; Neurobiology; Neurons; Neurosciences; Neurosciences Research; Oxytocin; Pharmacological Treatment; Physiological; Post-Traumatic Stress Disorders; Principal Investigator; Proteins; Psychiatry; Psychopharmacology; Psychophysiology; Publications; Publishing; Receptor Gene; Recovery; Research; Research Personnel; Risk; Risk Marker; Role; Running; Scientist; Signal Transduction; Sleep; Specialist; Stress; Symptoms; System; Training; Trauma; Traumatic Brain Injury; Treatment outcome; United States National Institutes of Health; Universities; Veterans; Work; alcohol comorbidity; biobank; biological adaptation to stress; blood-based biomarker; career; cell type; combat; cytotoxicity; dopamine system; endogenous cannabinoid system; exosome; follow-up; frontier; functional disability; genetic risk factor; health science research; heart rate variability; improved; indexing; longitudinal, prospective study; marine; mild traumatic brain injury; neuropathology; neuropsychopharmacology; novel; pharmacologic; post-trauma; pre-clinical; pre-clinical research; professor; prognostic tool; programs; psychosocial; receptor function; resilience; response; specific biomarkers; standard care; success; therapy development; tool; translational research program

Dr. Risbrough runs a cross-species translational research program to study mechanisms of trauma disorders including posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI). Her overall program aims to support development of novel treatments and diagnostic/prognostic tools for Veterans with PTSD and TBI. Dr. Risbrough focuses her preclinical research program on identifying mechanisms of risk and identifying potential novel treatments for PTSD using genetic, molecular and pharmacological tools in mice. She is known for her expertise in animal models of PTSD and the neurobiology of stress systems. Her current preclinical work includes identifying genetic risk markers for fear learning and extinction, identifying sleep and immune-system contributors to risk for PTSD and comorbid alcohol drinking and identifying novel treatments targeting dopamine and endocannabinoid systems to enhance fear-extinction based therapies. Her clinical research program includes identifying psychosocial, physiological and blood-based biomarkers of PTSD and TBI aimed at understanding mechanisms that impede recovery and induce functional impairment to improve intervention development. This program includes managing the San Diego VA Sleep Research Laboratory, the Psychophysiology Laboratory for the VA Center of Excellence for Stress and Mental Health (CESAMH), longitudinal PTSD/TBI Biorepository for CESAMH as well as her continued work as a Principal Investigator for the Marine Resiliency Study, a prospective longitudinal study of OIF/OEF Marines now in its 10 year follow up collection period. Finally, she also conducts clinical studies to identify novel pharmacological treatments for PTSD. Her research program is funded by NIMH, NIAAA, Department of Defense in addition to VA BLR&D and VA Center of Excellence for Stress and Mental Health funds.

里斯布鲁博士开展了一项跨物种转化研究计划，以研究 创伤性疾病，包括创伤后应激障碍 (PTSD) 和创伤性脑损伤 （创伤性脑损伤）。她的总体计划旨在支持新疗法的开发和 为患有 PTSD 和 TBI 的退伍军人提供诊断/预后工具。里斯布鲁博士专注于她 关于识别风险机制和识别潜在新颖性的临床前研究计划 使用遗传、分子和药理学工具对小鼠进行创伤后应激障碍（PTSD）治疗。她是众所周知的 表彰她在创伤后应激障碍（PTSD）动物模型和压力系统神经生物学方面的专业知识。她现在的 临床前工作包括识别恐惧学习和消退的遗传风险标记， 确定睡眠和免疫系统对创伤后应激障碍（PTSD）和共病酒精风险的影响因素 饮酒并确定针对多巴胺和内源性大麻素系统的新疗法 加强基于恐惧消除的疗法。她的临床研究计划包括识别 PTSD 和 TBI 的社会心理、生理和血液生物标志物旨在 了解阻碍恢复和诱导功能障碍改善的机制 干预发展。该计划包括管理圣地亚哥 VA 睡眠研究 实验室，退伍军人管理局压力和压力卓越中心的心理生理学实验室 心理健康 (CESAMH)，CESAMH 的纵向 PTSD/TBI 生物存储库以及她的 继续担任海洋复原力研究的首席研究员，该研究是一项前瞻性研究 OIF/OEF 海军陆战队的纵向研究目前正处于 10 年跟踪收集期。最后， 她还进行临床研究，以确定治疗创伤后应激障碍的新药物疗法。她 该研究项目由 NIMH、NIAAA、国防部以及 VA BLR&D 资助 和退伍军人管理局压力和心理健康基金卓越中心。